IQSTEL Inc.'s CEO Leandro Iglesias will participate in a live investor webinar on May 7, 2026, hosted by Force Family Office and interviewed by analyst Barry M. Sine. The discussion will cover IQSTEL's growth strategy, improving EBITDA, platform consolidation, and expansion into digital health, AI, and cybersecurity. This event offers investors insight into IQSTEL's transformation from a telecom operator to a technology platform enabling next-generation services. The company operates globally and is focusing on higher-margin services to drive future growth.
Fulcrum Therapeutics' stock dropped nearly 50% in after-hours trading after the company announced it is discontinuing its lead experimental drug, pociredir, for sickle cell disease. The decision follows FDA concerns about cancer risks linked to the d...
Inventiva, a clinical-stage biopharmaceutical company, has temporarily suspended trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 CEST. This suspension is at the company's request and precedes a planned financing operat...
Inventiva, a clinical-stage biopharmaceutical company, has temporarily halted trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 a.m. CEST. This pause is at the company's request and precedes a proposed financing transact...
The FDA has accepted Roche's New Drug Application for giredestrant, an oral selective estrogen receptor degrader (SERD), as an adjuvant treatment for early-stage ER-positive, HER2-negative breast cancer. The approval decision is expected by November ...
dsm-firmenich announced ongoing progress in its share repurchase program, buying back 184,000 shares between May 25-29, 2026, at an average price of €72.36 per share, totaling €13.3 million. This is part of a larger €540 million buyback initiated in ...
